Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHLW Lifts Conditions On Banyu's Hyperlipidemia Drug Lipovas

This article was originally published in PharmAsia News

Executive Summary

The first section on drugs of the Pharmaceutical Affairs and Food Sanitation Council at the Ministry of Health, Labor and Welfare lifted conditions on Banyu Pharmaceutical's hyperlipidemia drug Lipovas (simvastatin). Imposed upon approval in 2001, the conditions required Banyu to study the relationship between increased dosage and the onset of rhabdomyolysis, but no cases of rhabdomyolysis have been reported and creatine kinase counts, directly related to the disease, are lower after market launch compared to those reported in clinic trials. (Click here for more - Japanese language)

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts